T P Tanpitukpongse1, M A Mazurowski1, J Ikhena2, J R Petrella3. 1. From the Department of Radiology (T.P.T., M.A.M., J.R.P.), Duke University Medical Center, Durham, North Carolina. 2. Duke University School of Medicine (J.I.), Durham, North Carolina. 3. From the Department of Radiology (T.P.T., M.A.M., J.R.P.), Duke University Medical Center, Durham, North Carolina jeffrey.petrella@duke.edu.
Abstract
BACKGROUND AND PURPOSE: Alzheimer disease is a prevalent neurodegenerative disease. Computer assessment of brain atrophy patterns can help predict conversion to Alzheimer disease. Our aim was to assess the prognostic efficacy of individual-versus-combined regional volumetrics in 2 commercially available brain volumetric software packages for predicting conversion of patients with mild cognitive impairment to Alzheimer disease. MATERIALS AND METHODS: Data were obtained through the Alzheimer's Disease Neuroimaging Initiative. One hundred ninety-two subjects (mean age, 74.8 years; 39% female) diagnosed with mild cognitive impairment at baseline were studied. All had T1-weighted MR imaging sequences at baseline and 3-year clinical follow-up. Analysis was performed with NeuroQuant and Neuroreader. Receiver operating characteristic curves assessing the prognostic efficacy of each software package were generated by using a univariable approach using individual regional brain volumes and 2 multivariable approaches (multiple regression and random forest), combining multiple volumes. RESULTS: On univariable analysis of 11 NeuroQuant and 11 Neuroreader regional volumes, hippocampal volume had the highest area under the curve for both software packages (0.69, NeuroQuant; 0.68, Neuroreader) and was not significantly different (P > .05) between packages. Multivariable analysis did not increase the area under the curve for either package (0.63, logistic regression; 0.60, random forest NeuroQuant; 0.65, logistic regression; 0.62, random forest Neuroreader). CONCLUSIONS: Of the multiple regional volume measures available in FDA-cleared brain volumetric software packages, hippocampal volume remains the best single predictor of conversion of mild cognitive impairment to Alzheimer disease at 3-year follow-up. Combining volumetrics did not add additional prognostic efficacy. Therefore, future prognostic studies in mild cognitive impairment, combining such tools with demographic and other biomarker measures, are justified in using hippocampal volume as the only volumetric biomarker.
BACKGROUND AND PURPOSE:Alzheimer disease is a prevalent neurodegenerative disease. Computer assessment of brain atrophy patterns can help predict conversion to Alzheimer disease. Our aim was to assess the prognostic efficacy of individual-versus-combined regional volumetrics in 2 commercially available brain volumetric software packages for predicting conversion of patients with mild cognitive impairment to Alzheimer disease. MATERIALS AND METHODS: Data were obtained through the Alzheimer's Disease Neuroimaging Initiative. One hundred ninety-two subjects (mean age, 74.8 years; 39% female) diagnosed with mild cognitive impairment at baseline were studied. All had T1-weighted MR imaging sequences at baseline and 3-year clinical follow-up. Analysis was performed with NeuroQuant and Neuroreader. Receiver operating characteristic curves assessing the prognostic efficacy of each software package were generated by using a univariable approach using individual regional brain volumes and 2 multivariable approaches (multiple regression and random forest), combining multiple volumes. RESULTS: On univariable analysis of 11 NeuroQuant and 11 Neuroreader regional volumes, hippocampal volume had the highest area under the curve for both software packages (0.69, NeuroQuant; 0.68, Neuroreader) and was not significantly different (P > .05) between packages. Multivariable analysis did not increase the area under the curve for either package (0.63, logistic regression; 0.60, random forest NeuroQuant; 0.65, logistic regression; 0.62, random forest Neuroreader). CONCLUSIONS: Of the multiple regional volume measures available in FDA-cleared brain volumetric software packages, hippocampal volume remains the best single predictor of conversion of mild cognitive impairment to Alzheimer disease at 3-year follow-up. Combining volumetrics did not add additional prognostic efficacy. Therefore, future prognostic studies in mild cognitive impairment, combining such tools with demographic and other biomarker measures, are justified in using hippocampal volume as the only volumetric biomarker.
Authors: D P Devanand; G Pradhaban; X Liu; A Khandji; S De Santi; S Segal; H Rusinek; G H Pelton; L S Honig; R Mayeux; Y Stern; M H Tabert; M J de Leon Journal: Neurology Date: 2007-03-13 Impact factor: 9.910
Authors: Shannon L Risacher; Andrew J Saykin; John D West; Li Shen; Hiram A Firpi; Brenna C McDonald Journal: Curr Alzheimer Res Date: 2009-08 Impact factor: 3.498
Authors: Bradley T Wyman; Danielle J Harvey; Karen Crawford; Matt A Bernstein; Owen Carmichael; Patricia E Cole; Paul K Crane; Charles DeCarli; Nick C Fox; Jeffrey L Gunter; Derek Hill; Ronald J Killiany; Chahin Pachai; Adam J Schwarz; Norbert Schuff; Matthew L Senjem; Joyce Suhy; Paul M Thompson; Michael Weiner; Clifford R Jack Journal: Alzheimers Dement Date: 2012-10-27 Impact factor: 21.566
Authors: Fabio Raman; Sameera Grandhi; Charles F Murchison; Richard E Kennedy; Susan Landau; Erik D Roberson; Jonathan McConathy Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Carol E Franz; Sean N Hatton; Richard L Hauger; M Alexandra Kredlow; Anders M Dale; Lisa Eyler; Linda K McEvoy; Christine Fennema-Notestine; Donald Hagler; Kristen C Jacobson; Ruth E McKenzie; Matthew S Panizzon; Daniel E Gustavson; Hong Xian; Rosemary Toomey; Asad Beck; Samantha Stevens; Xin Tu; Michael J Lyons; William S Kremen Journal: Brain Imaging Behav Date: 2020-08 Impact factor: 3.978
Authors: Mary Kay Ross; Cyrus Raji; Kristine L Lokken; Dale E Bredesen; Jared C Roach; Cory C Funk; Nathan Price; Noa Rappaport; Leroy Hood; James R Heath Journal: J Alzheimers Dis Parkinsonism Date: 2021-08-25
Authors: Chul-Ho Sohn; Dong Young Lee; Koung Mi Kang; Min Soo Byun; Jun Ho Lee; Dahyun Yi; Younghwa Lee; Jun-Young Lee; Yu Kyeong Kim; Bo Kyung Sohn; Roh-Eul Yoo; Tae Jin Yun; Seung Hong Choi; Ji-Hoon Kim Journal: Neuropsychiatr Dis Treat Date: 2020-07-22 Impact factor: 2.570
Authors: Aozhou Wu; A Richey Sharrett; Rebecca F Gottesman; Melinda C Power; Thomas H Mosley; Clifford R Jack; David S Knopman; B Gwen Windham; Alden L Gross; Josef Coresh Journal: JAMA Netw Open Date: 2019-05-03
Authors: Bihong T Chen; Sean K Sethi; Taihao Jin; Sunita K Patel; Ningrong Ye; Can-Lan Sun; Russell C Rockne; E Mark Haacke; James C Root; Andrew J Saykin; Tim A Ahles; Andrei I Holodny; Neal Prakash; Joanne Mortimer; James Waisman; Yuan Yuan; George Somlo; Daneng Li; Richard Yang; Heidi Tan; Vani Katheria; Rachel Morrison; Arti Hurria Journal: Breast Cancer Res Date: 2018-05-02 Impact factor: 6.466
Authors: Sarah C McEwen; David A Merrill; Jennifer Bramen; Verna Porter; Stella Panos; Scott Kaiser; John Hodes; Aarthi Ganapathi; Lesley Bell; Tess Bookheimer; Ryan Glatt; Molly Rapozo; Mary Kay Ross; Nathan D Price; Daniel Kelly; Cory C Funk; Leroy Hood; Jared C Roach Journal: Alzheimers Dement (N Y) Date: 2021-07-20